Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. - Wikidata - wikimedia - TriplyDB

Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia.

Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q33957743

about

Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia Functional and prognostic role of ZAP-70 in chronic lymphocytic leukaemia Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia iHMMune-align: hidden Markov model-based alignment and identification of germline genes in rearranged immunoglobulin gene sequences.Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells.HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses.Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks.Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia.Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors.How I treat CLL up front.Lymphoid malignancies: the dark side of B-cell differentiation.Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors.Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status.IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations Somatic hypermutation patterns in germinal center B cell malignancies.Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification.Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia.V(H)3-21 gene usage in chronic lymphocytic leukemia--characterization of a new subgroup with distinct molecular features and poor survival.Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.Specific chromosomal IG translocations have different prognoses in chronic lymphocytic leukemia.Novel molecular diagnostic and therapeutic targets in chronic lymphocytic leukaemia.Comprehensive characterization of immunoglobulin gene rearrangements in patients with chronic lymphocytic leukaemia.B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.The immunoglobulin genes and chronic lymphocytic leukemia (CLL).Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia.Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3.New molecular markers in resistant B-CLL.Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia.The immunoglobulin genes: structure and specificity in chronic lymphocytic leukemia.Molecular genetic analysis of haematological malignancies II: Mature lymphoid neoplasms.Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia

P2860

Q26830323-B8F1F7F7-E988-4611-BD64-61FC72186E8D Q28282822-F0603184-D3E8-43D7-A62D-EF52DC23BAA8 Q29048141-50FCBE23-E142-4C11-B3C6-27B337ED9DB6 Q33282962-22797C1F-7B04-41A4-9D54-36E916DD889A Q33494799-763BF31C-BF6F-46DD-BF57-4D27E87083C2 Q33831931-B5DC3C58-94E9-4F7B-8606-C0FC5B9E8700 Q33862792-8B7539C1-3EFE-41B5-8920-173694ADC7DE Q33886052-400DEC36-DDDA-49ED-BC9E-A18F72403A3A Q34056568-2055C1A9-DF92-41E5-BE5D-91872D2746F4 Q34095630-BEAD102F-628E-4316-807C-21FC34DE9054 Q34137158-B9914C4D-F133-40A8-AB45-F984A7DBCA99 Q34162187-E1898371-5AFC-4CAF-9D53-D63FBEF49A42 Q34166551-C2E18EC5-511D-4EC6-B016-D883ED07CF72 Q34371084-254BB3BB-2745-4F41-95DD-21689B01A02C Q34521343-D5D85D3F-62ED-4D50-9056-124DF62EC080 Q34804388-48287558-D8F7-4B16-9629-A5B755A1D7EC Q34830865-0C8794BF-2D68-4739-B7DD-78DF17F24646 Q35029461-A6DCD8D3-85AF-4357-98A6-AF828C9F6F64 Q35552528-EFB2DE74-3104-490E-B26E-4B3E268F839F Q35628846-D5901863-0063-4E89-AEAE-2DB23159B484 Q35690880-C7E530B7-6679-4616-B692-2B4790F7A9C7 Q35752827-97EAC330-E4E9-4FCF-ADC3-68021A515855 Q35790006-E2A17325-69C5-4EA5-87A8-BE9CC69CD84C Q35824945-87CAB8B5-26C2-4AD0-8AFF-7E1C15A54331 Q35854960-9FDDD287-A7A6-4451-BD26-5FF8B5F8F6A3 Q35867812-8AA68047-B666-4E6B-930B-CB0D5066D410 Q35954301-2EDA05DF-D403-4AAB-A6D2-BC42AA00FDA1 Q36083000-138FCA70-D024-49FD-8097-0AAF2F82D9D6 Q36216608-DE1CEF0F-289F-4C02-8705-D6EC4A2133AD Q36227244-FF8079F9-83C7-44E6-B2C5-20300BB29705 Q36399593-AAC91ABC-5370-47FF-8A28-3C701741E93D Q36491858-5D5A5D8A-8C44-4745-9902-583428B198F0 Q36497411-89CD2436-00FD-4E9A-91D1-D659DDE6BDCA Q36611156-064596F9-6FEB-4F4B-AD2B-70B708EED682 Q36658038-F62B5667-7624-409F-8540-CAB9CD711E73 Q36826893-5C283CF4-3961-465F-8781-6484164AFD1A Q36849336-44C65E9C-739C-4A38-A25C-AE537D0E57AB Q36852855-9443B167-D645-4DC3-9535-D02D6B1F10D6 Q36872779-705E0EC1-D204-4A6D-95FB-D80391B0F435 Q36942667-1ABDFF3A-9DF4-4BD8-9BC0-40FAE96FF0DF

P2860

Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q33957743

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Somatically mutated Ig V(H)3-2 ...... chronic lymphocytic leukemia.

@ast

Somatically mutated Ig V(H)3-2 ...... chronic lymphocytic leukemia.

@en

type

label

Somatically mutated Ig V(H)3-2 ...... chronic lymphocytic leukemia.

@ast

Somatically mutated Ig V(H)3-2 ...... chronic lymphocytic leukemia.

@en

prefLabel

Somatically mutated Ig V(H)3-2 ...... chronic lymphocytic leukemia.

@ast

Somatically mutated Ig V(H)3-2 ...... chronic lymphocytic leukemia.

@en

P1433

Q33957743-3AF998B7-0E6E-4682-88C5-8B4FC6F883DE

P1476

Q33957743-F903830C-2833-4305-B929-543EACE77614

P2093

Q33957743-49A88EA7-5C00-4D54-AFF4-E725F6242BA0

Q33957743-4D4F7B20-FAD1-46C7-88AA-B32D79789FAF

Q33957743-5AAC6C1E-D929-4724-84AD-7E124D5F8CB1

Q33957743-63D9223E-034B-4451-BB52-F852CBDD2BDE

Q33957743-692137D5-B3CC-49D4-9F60-2F8C31E5731F

Q33957743-69AC905B-272F-433C-8B1C-43D75BC7004D

Q33957743-7C27B20D-53A0-46B9-89E5-237ECDFB8481

Q33957743-92745D35-5044-434D-8150-DDB2CFCA1B68

Q33957743-D70F3AF3-CE1A-4949-9D95-EF3345841E1B

Q33957743-E8E566FF-3101-4A7C-8640-88A4029AF0AB

P304

Q33957743-131D664C-57FC-4192-80E3-6E497988C597

P31

Q33957743-A4BC89C8-5E2A-4941-BA95-BB2728193B58

P356

Q33957743-FF1FBB14-CB0D-405C-980B-6FD036412F40

P407

Q33957743-EB09838C-B8A1-4FD0-A410-955CAD18C8F5

P433

Q33957743-61AC93D1-3E4A-4029-AF32-5B5D4EE0AFB9

P478

Q33957743-3DC80714-97C7-4201-90E2-E8E72E52A50A

P50

Q33957743-9317E41A-1B2F-47B8-A993-6E026575B1FF

Q33957743-BAC441AD-106B-4DDF-BB2E-A7B06DBC8AAE

P577

Q33957743-BD13E851-CD22-4835-9E4C-AB66F18ADBB4

P698

Q33957743-172F6226-0AB2-4809-A183-458A6E422D31

P921

Q33957743-3587FD11-2A9C-4391-991A-0D72F91F1820

Q33957743-B91BC905-2F2F-439E-BD33-603EA3343E76

P356

BLOOD.V99.6.2262

P1433

P1476

Somatically mutated Ig V(H)3-2 ...... chronic lymphocytic leukemia.

@en

P2093

Anna Johnson

http://www.w3.org/2001/XMLSchema#string

Christer Sundström

http://www.w3.org/2001/XMLSchema#string

Gerard Tobin

http://www.w3.org/2001/XMLSchema#string

Gunilla Enblad

http://www.w3.org/2001/XMLSchema#string

Ingrid Thörn

http://www.w3.org/2001/XMLSchema#string

Jan Sällström

http://www.w3.org/2001/XMLSchema#string

Johan Botling

http://www.w3.org/2001/XMLSchema#string

Magnus Hultdin

http://www.w3.org/2001/XMLSchema#string

Richard Rosenquist

http://www.w3.org/2001/XMLSchema#string

Ulf Thunberg

http://www.w3.org/2001/XMLSchema#string

P304

2262-2264

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD.V99.6.2262

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11877310

http://www.w3.org/2001/XMLSchema#string

P921